SANA | Sana Biotechnology, Inc.

Index- P/E- EPS (ttm)-1.69 Insider Own3.10% Shs Outstand191.23M Perf Week3.04%
Market Cap1.17B Forward P/E- EPS next Y-1.49 Insider Trans-8.18% Shs Float169.28M Perf Month16.91%
Income-320.20M PEG- EPS next Q-0.43 Inst Own91.20% Short Float / Ratio16.68% / 20.75 Perf Quarter64.87%
Sales- P/S- EPS this Y33.10% Inst Trans1.96% Short Interest28.24M Perf Half Y28.86%
Book/sh2.24 P/B2.87 EPS next Y13.40% ROA-37.20% Target Price10.00 Perf Year29.38%
Cash/sh1.92 P/C3.34 EPS next 5Y- ROE-60.00% 52W Range2.99 - 9.55 Perf YTD62.78%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-32.67% Beta-
Dividend %- Quick Ratio3.60 Sales past 5Y- Gross Margin- 52W Low115.05% ATR0.56
Employees424 Current Ratio3.60 Sales Q/Q- Oper. Margin- RSI (14)54.02 Volatility10.29% 9.35%
OptionableYes Debt/Eq0.00 EPS Q/Q-153.90% Profit Margin- Rel Volume0.92 Prev Close6.10
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.36M Price6.43
Recom2.40 SMA20-1.57% SMA5023.94% SMA20027.20% Volume1,250,569 Change5.41%
Date Action Analyst Rating Change Price Target Change
May-02-23Initiated H.C. Wainwright Neutral
Mar-01-21Initiated Morgan Stanley Overweight $40
Mar-01-21Initiated JP Morgan Neutral $35
Mar-01-21Initiated Goldman Neutral $40
Mar-01-21Initiated BofA Securities Buy $45
May-31-23 04:05PM
May-22-23 07:33AM
May-16-23 06:00AM
May-08-23 04:35PM
04:05PM Loading…
May-04-23 01:56PM
May-03-23 04:05PM
May-02-23 04:30PM
Apr-24-23 04:05PM
Apr-20-23 10:07AM
Apr-19-23 04:05PM
Apr-17-23 09:55AM
06:17AM Loading…
Apr-14-23 10:27AM
Apr-13-23 09:00AM
Apr-12-23 04:05PM
Apr-10-23 04:05PM
Mar-24-23 03:20PM
Mar-16-23 04:05PM
Mar-14-23 04:53PM
Mar-01-23 04:05PM
Feb-10-23 08:18AM
Feb-02-23 04:05PM
Jan-26-23 04:05PM
Jan-03-23 04:05PM
Dec-11-22 05:30PM
Dec-01-22 12:11AM
10:55AM Loading…
Nov-30-22 10:55AM
Nov-29-22 04:05PM
Nov-17-22 01:58PM
Nov-14-22 04:05PM
Nov-03-22 09:07AM
Nov-02-22 04:05PM
Oct-18-22 07:43AM
Sep-09-22 04:05PM
Sep-03-22 08:39AM
Aug-09-22 11:54AM
Aug-04-22 04:05PM
Jun-17-22 09:00AM
Jun-13-22 04:05PM
Jun-07-22 04:05PM
Jun-02-22 01:55AM
Jun-01-22 04:05PM
May-12-22 05:40PM
May-11-22 07:19AM
May-10-22 04:05PM
May-04-22 04:05PM
May-02-22 04:35PM
Mar-24-22 04:12PM
Mar-20-22 08:02AM
Mar-16-22 08:30AM
Mar-09-22 04:05PM
Mar-08-22 04:35PM
Feb-28-22 09:00AM
Feb-17-22 04:38PM
Feb-15-22 10:05AM
Jan-27-22 06:23PM
Jan-11-22 06:56AM
Jan-10-22 04:30PM
Jan-04-22 04:05PM
Dec-17-21 08:00AM
Dec-13-21 07:38PM
Dec-12-21 09:05AM
Dec-11-21 05:38AM
Nov-08-21 04:05PM
Nov-04-21 09:07AM
Oct-19-21 03:55PM
Oct-13-21 10:00AM
Sep-13-21 11:20AM
Sep-07-21 04:05PM
Sep-02-21 01:13PM
Aug-09-21 02:00AM
Aug-04-21 04:05PM
Jul-14-21 04:10PM
Jun-26-21 10:42AM
Jun-14-21 07:51PM
Jun-02-21 04:05PM
May-25-21 06:00AM
May-19-21 09:01AM
May-05-21 04:05PM
May-04-21 04:05PM
Apr-27-21 04:35PM
Apr-09-21 09:00AM
Mar-30-21 09:30AM
Mar-24-21 04:10PM
Mar-17-21 09:00AM
Feb-08-21 05:24PM
Feb-03-21 11:22PM
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG299 and SG242 that targets CD19+ cancer cells in patients with non-Hodgkin Lymphoma (NHL), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL); SG221 and SG239 for the treatment of multiple myeloma; and SG233, a CD22 CAR for the treatment of NHL, CLL, and ALL. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255, a B cell maturation antigen directed allogeneic CAR T for multiple myeloma; SC45, the PSC-derived pancreatic islet cells for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, Huntington's disease, and other astrocytic diseases. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is based in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Flagship Ventures Fund V Gener10% OwnerMay 26Sale6.2382,000510,5731,425,334May 26 08:00 PM
Flagship Ventures Fund V Gener10% OwnerMay 25Sale6.35115,372732,8661,434,664May 26 08:00 PM
Flagship Ventures Fund V Gener10% OwnerMay 24Sale6.57347,8702,283,8361,447,791May 26 08:00 PM
MacDonald James J.EVP & General CounselJun 13Option Exercise1.4866,79698,858497,396Jun 15 06:16 PM